Yannis Hadjiyannis, Jennifer M Jones, Irina Chibisov, Joseph Kiss, Kim Gabert, Joan Sevcik, Suzanne Bakdash, Anna Binstock, Carolyn Kilonsky, Kristiina Parviainen, Alesia Kaplan
Anti-PP1PK alloimmunization is rare given ubiquitous P1PK expression. Prevention of recurrent miscarriages and hemolytic disease of the fetus and newborn (HDFN) in pregnant individuals with anti-PP1PK antibodies has relied upon individual reports. Here, we demonstrate the successful management of maternal anti-PP1PK alloimmunization in a 23-year-old, G2P0010, with therapeutic plasma exchange (TPE), intravenous immunoglobulin (IVIG), and monitoring of anti-PP1Pk titers. Twice-weekly TPE (1.5 plasma volume [PV], 5% albumin replacement) with weekly titers and IVIG (1 g/kg) was initiated at 9 weeks of gestation (WG)...
June 2024: Journal of Clinical Apheresis